Guangzhou Baiyunshan subsidiary to acquire Zhejiang Pharmaceutical for 500.5m yuan

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited announced its subsidiary, Guangzhou Pharmaceutical, will acquire 100% equity in Zhejiang Provincial Pharmaceutical Industry Co., Ltd. for 50,050.00万元. The acquisition, approved by the board on December 10, 2025, aims to optimize Guangzhou Pharmaceutical's industrial layout in Eastern China and enhance its coverage of the domestic terminal market.

Zhejiang Provincial Pharmaceutical Industry Co., Ltd. operates in Zhejiang province, specializing in pharmaceutical distribution, including ephedrine, caffeine, and Class II narcotics, with annual sales revenue exceeding 4 billion yuan. The transaction is set to close following anti-monopoly review and other necessary approvals.

The transfer price of 50,050.00万元 was based on a public bidding process, following an appraised value of 39,223.39万元 for 100% equity as of May 31, 2025. Guangzhou Pharmaceutical will use its own funds for the acquisition, which is not expected to negatively impact its operations or financial status.